

SANTEN PHARMACEUTICAL CO., LTD.



Half Year Ended September 30, 2015

Corporate Communication Group Tel: 06-4802-9360 Fax: 06-6359-3827 E-mail: ir@santen.co.jp Stock Code: 4536

Contents

Financial highlights		2
Consolidated financial su	mmary (J-GAAP)	2
Consolidated financial su	mmary (IFRS, and Core base)	2
Consolidated balance she	ets summary	2
Consolidated financial in	dexes	2
Exchange rates		2
Consolidated information		4
Consolidated statements of income and co	omprehensive income	4
Statements of income and comprehensive	•	5
Operating result details		6
	d administrative expenses, R&D expenses	6
	ome and expenses / Finance income and Finance expense	6
Sales details		7
Sales by segment		7
Oversea sales by region		7
Oversea profit contributio	on (IFRS)	7
Sales of major prescription		8
Consolidated balance sheets (J-GAAP)	n phurmaceuteurs	10
		10
Liabilities and net assets		11
Consolidated Statement of financial posit	ion (IFRS)	12
Assets		12
Equity and liabilities		13
Consolidated statements of cash flows		13
Other consolidated information		16
■R&D expenditures		16
		16
Depreciation and amortiz	ation	16
Number of employees		16
Reference information		10
Research & development		17
	harmaceuticals (Clinical trials)	17
Changes from August 4,		17
Pharmaceutical market in Japan	2013	10
	lth Insurance (NHI) drug prices	19
	fur insurance (IVHI) drug prices	19
Market shares		19
	utic area - prescription ophthalmics	
Stock information	:::- England 1.t. market)	20
Stock price (Tokyo Secur	Thes Exchange 1st market)	20
Major shareholders		20
Major stock information		20
Breakdown of shareholdi		21
	ng by number of shareholders	21
		22
Consolidated subsidiaries News releases		23

Santen group has unified the accounting period from the fiscal year ended March 31, 2014, for voluntary adoption of International Financial Reporting Standards (IFRS) from the fiscal year ending March 31, 2015. In this data book, performance for the unification of accounting period is noted as (*), and financial results for the previous 12 month period are shown as [12month]. Financial results before the fiscal year ended March 31, 2013 are based on the previous 12 month performance.

Results contained in the column marked 2014[12month] provide precise and comparable 12 month results including for subsidiaries using different fiscal year periods.

The company implemented a 5-for-1 stock split on April 1, 2015. Figures in the column 2014.3[IFRS] are adjusted assuming the new, post-split number of shares for comparison purposes.

Forecasts in this report are based on the currently available information. Forecasts in this report are based on the currently available information. Actual results may differ materially depending on a number of factors including adverse economic conditions etc. Actual results may differ materially depending on a number of factors including adverse economic conditions, delays in new products launch, currency exchange rate, legislative and regulatory developments.

Financial highlights

Consolidated financial summary (J-GAAP)

Half year/year to	9/2013	3/2014*	3/2014 [12month]	9/2014	3/2015	9/2015	% Change	3/2016 Forecast	% Change
Net sales	69,263	148,663	146,013	71,925	161,881	—	-	—	-
Operating income	14,457	27,414	28,835	13,194	33,516	_	_	_	_
Ordinary income	14,861	27,924	29,332	13,602	34,516	_	_	_	_
Net income	8,994	17,109	18,922	9,099	22,570	_	_	_	_
Dividends per share (yen)	50	100	100	50	110	_	_	_	_
Dividend payout (%)	45.9%	48.2%	43.6%	36.6%	40.3%	_	_	_	_

Consolidated financial summary (IFRS, and Core base)

Half year/year to			3/2014	9/2014	3/2015	9/2015	% Change	3/2016 Forecast	% Change
Revenue	-	—	146,260	71,920	161,831	97,873	36.1	186,500	15.2
Operating profit	-	—	29,878	14,235	35,374	65,385	359.3	78,000	120.5
Net profit for the year	-	—	19,718	9,759	24,032	43,657	347.3	52,500	118.9
Dividends per share (yen)		—	100	50	110	_	—	_	_
Dividend payout (%)	-	_	41.9%	42.3%	37.8%	11.4%	-73.1	18.9%	_
Core operating profit	_	_	30,403	15,298	39,088	24,541	60.4	40,300	3.1
Net profit for the year	_	_	19,813	10,138	25,948	16,392	61.7	26,900	3.7
Core ROE	_	_	11.2%	10.6%	13.0%	14.2%	33.4	_	_
Core EPS (yen)	_	—	48.0	24.6	62.8	39.7	61.5	65.1	3.6
PER (times)		_	19.1	50.0	27.9	40.3	-19.4	_	_

Consolidated balance shee			(Millio	ns of yen)				
		J-GAAP		IFRS				
Half year/year to	9/2013	3/2014*	3/2014 [12month]	9/2014	3/2015	9/2015	% Change	
Total assets	211,690	231,105	I	268,708	304,200	352,080	31.0	
Net assets	171,526	181,209	I	194,637	211,779	250,899	28.9	
Interest-bearing debts	171	110	-	35,127	37,161	31,248	-11.0	

Consolidated financial indexes

		J-GAAP	1	IFRS						
Half year/year to	9/2013	3/2014*	3/2014 [12month]	9/2014	3/2015	9/2015	% Change	3/2016 Forecast	% Change	
EPS (yen)	108.99	207.29	229.26	23.63	58.18	105.55	346.7	127.04	118.4	
BPS (yen) #1	2,073.17	2,189.50	2,234.70	471.23	511.14	606.31	28.7	—	_	
Debt equity ratio (times)	0.0	0.0	0.0	0.2	0.2	0.1	-31.0	—	_	
PER (times)	21.9	22.1	20.0	52.0	30.1	15.1	-71.0	—	-	
PBR (times)	2.3	2.1	2.1	2.6	3.4	2.6	1.2	—	_	
ROE (%) #1	10.7	9.9	10.8	10.2	12.0	37.8	270.1	22.5	_	
ROA (%)	8.7	7.9	8.8	7.4	8.9	26.6	261.5	_	_	
Equity ratio(%) #1	80.8	78.2	79.3	72.2	69.6	71.0	-1.6	—	_	
Free cash flows (millions of yen) #2	8,653	21,172	_	2,144	20,105	10,592	394.0	_	_	
EBITDA (millions of yen) #3	15,322	29,812	_	7,014	31,081	39,138	458.0	_	_	

#1 BPS (net assets per share), ROE (return on equity) and equity ratios are based on the IFRS inputs of equity per share attributable to owners of the parent, net profit attributable to owners of parent and ratio of equity attributable to owners of the parent.

#2 Free cash flows = (Cash flows from operating activities) - (Capital expenditures)

Not adjusting increase/decrease in trade receivables for fiscal years ending on holidays.

#3 EBITDA = (Income before income taxes) + (Interest expense) + (Depreciation and amortization)


■Exchange rates						(Yen)
Half year/year to	9/2013	3/2014*	3/2014 [12month]	9/2014	3/2015	9/2015
Exchange rate: US dollar	98.31	100.04	100.04	103.12	110.14	121.82
: Euro	127.47	132.98	132.34	138.98	139.01	134.95
: RMB	15.25	15.93	15.72	16.71	17.84	19.67


* After reflecting unification of accounting period.


(Millions of yen)


Financial highlights


Consolidated Financial summary (Graph)




















Consolidated Information Consolidated statements of income and comprehensive income

■Consolidated financial summary (J-GAAP)

			2/2014			
Half year/year to	9/2013	3/2014*	3/2014 [12month]	9/2014	3/2015	
Net sales	69,263	148,663	146,013	71,925	161,881	
Cost of sales	27,160	58,104	57,171	26,593	56,423	
(Percentage of net sales)	39.2%	39.1%	39.2%	37.0%	34.9%	
Gross profit	42,102	90,558	88,842	45,332	105,458	
(Percentage of net sales)	60.8%	60.9%	60.8%	63.0%	65.1%	
Selling, general and administrative expenses	27,645	63,144	60,006	32,138	71,942	
(Percentage of net sales)	39.9%	42.5%	41.1%	44.7%	44.4%	
R&D expenditures	8,078	19,040	18,235	8,488	18,062	
(Percentage of net sales)	11.7%	12.8%	12.5%	11.8%	11.2%	
Operating income	14,457	27,414	28,835	13,194	33,516	
(Percentage of net sales)	20.9%	18.4%	19.7%	18.3%	20.7%	
Non-operating income	560	975	952	583	1,333	
Non-operating expenses	156	465	455	176	333	
Ordinary income	14,861	27,924	29,332	13,602	34,516	
(Percentage of net sales)	21.5%	18.8%	20.1%	18.9%	21.3%	
Extraordinary gain	_	473	473	59	155	
Extraordinary loss	878	1,504	1,014	—	344	
Income before income taxes	13,983	26,893	28,792	13,661	34,327	
(Percentage of net sales)	20.2%	18.1%	19.7%	19.0%	21.2%	
Income taxes - current	5,467	11,762	11,255	4,575	12,600	
Income taxes - deferred	-478	-1,978	-1,385	-13	-843	
Income before minority interests	8,994	17,109	18,922	9,099	22,570	
Net income	8,994	17,109	18,922	9,099	22,570	
(Percentage of net sales)	13.0%	11.5%	13.0%	12.7%	13.9%	
Income before minority interests	8,994	17,109	18,922	9,099	22,570	
Other comprehensive income	2,695	8,269	10,188	1,756	8,708	
Comprehensive income	11,689	25,378	29,111	10,855	31,278	

* After reflecting unification of accounting period.

Consolidated information Statements of income and comprehensive income

■IFRS (Full Base)

					(
Year ended March 31	2013.9	2014.3	2014.9	2015.3	2015.9	% Change 2015/2014
Revenue	_	146,260	71,920	161,831	97,873	36.1
Cost of sales	_	-57,353	-26,587	-56,373	-36,501	37.3
(Percentage of revenue)	_	39.2%	37.0%	34.8%	37.3%	—
Gross profit	-	88,907	45,333	105,458	61,372	35.4
(Percentage of revenue)	_	60.8%	63.0%	65.2%	62.7%	—
Selling, general and administrative expenses		-41,642	-21,865	-48,893	-27,588	26.2
(Percentage of revenue)		28.5%	30.4%	30.2%	28.2%	—
Research and development expenses		-16,862	-8,170	-17,477	-9,243	13.1
(Percentage of revenue)	_	11.5%	11.4%	10.8%	9.4%	—
Amortization on intangible assets associated with products	_	-190	-1,297	-3,979	-2,999	131.2
(Percentage of revenue)	_	0.1%	1.8%	2.5%	3.1%	—
Other income	_	681	288	723	44,705	—
Other expense	_	-1,016	-54	-458	-861	—
Operating profit	_	29,878	14,235	35,374	65,385	359.3
(Percentage of revenue)	_	20.4%	19.8%	21.9%	66.8%	—
Finance income	-	916	459	768	450	-2.0
Finance expense	_	-433	-154	-279	-500	224.8
Profit before tax	_	30,361	14,540	35,863	65,335	349.4
(Percentage of revenue)	_	20.8%	20.2%	22.2%	66.8%	—
Income tax expenses	_	-10,643	-4,781	-11,831	-21,679	353.5
Net profit for the year		19,718	9,759	24,032	43,657	347.3
(Percentage of revenue)		13.5%	13.6%	14.9%	44.6%	—
ROE (%)	_	11.1	37.8	12.0	22.5	—

■IFRS (Core Base)

(Millions of yen)

Year ended March 31	2013.9	2014.3	2014.9	2015.3	2015.9	% Change 2015/2014
Revenue	_	146,260	71,920	161,831	97,873	36.1
Cost of sales	-	-57,353	-26,587	-56,373	-36,501	37.3
(Percentage of revenue)	-	39.2%	37.0%	34.8%	37.3%	—
Gross profit	_	88,907	45,333	105,458	61,372	35.4
(Percentage of revenue)		60.8%	63.0%	65.2%	62.7%	_
Selling, general and administrative expenses	-	-41,642	-21,865	-48,893	-27,588	26.2
(Percentage of revenue)	-	28.5%	30.4%	30.2%	28.2%	—
Research and development expenses	-	-16,862	-8,170	-17,477	-9,243	13.1
(Percentage of revenue)	-	11.5%	11.4%	10.8%	9.4%	—
Operating profit	_	30,403	15,298	39,088	24,541	60.4
(Percentage of revenue)		20.8%	21.3%	24.2%	25.1%	_
Profit before tax	-	30,403	15,298	39,088	24,541	60.4
(Percentage of revenue)	_	20.8%	21.3%	24.2%	25.1%	—
Income tax expenses	-	-10,590	-5,160	-13,140	-8,149	57.9
Net profit for the year	-	19,813	10,138	25,948	16,392	61.7
(Percentage of revenue)		13.6%	14.1%	16.0%	16.7%	_
ROE (%)	_	11.2	10.6	13.0	14.2	_

Consolidated Information Consolidated statements of income details

■ Major Selling, general and administrative expenses, R&D expenses (Milli										
	J-GAAP									
Half year/year to	9/2013	3/2014*	3/2014 [12month]	9/2014	3/2015	9/2015	Change over previous half year (%)			
Personnel expenses	8,294	17,822	17,092	8,830	18,381	10,786	22.2			
Sales promotion expenses	2,642	6,751	6,257	3,203	7,267	3,930	22.7			
Royalty expenses	1,130	2,547	2,515	1,192	2,916	1,598	34.1			
Advertising expenses	831	1,589	1,439	823	2,041	1,098	33.5			
R&D expenses	8,078	19,040	18,235	8,170	17,477	9,243	13.1			

o deninia -

■ Major Non-operating income and expenses / Finance income and Finance expense (Millions of yen)

		J-GAAP		IFRS					
Half year/year to	9/2013	3/2014*	3/2014 [12month]	9/2014	3/2015	9/2015	Change over previous half year (%)		
Interest and dividend income	280	601	598	313	620	309	-1.4		
Gain on insurance received	147	147	147	144	144	140	-3.0		
Interest expense	3	5	9	34	91	48	39.4		

* After reflecting unification of accounting period.

Sales details

Sales by segment							(Milli	ons of yen)
		J-GAAP				IFRS		
Half year/year to	9/2013	3/2014*	3/2014 [12month]	9/2014	3/2015	9/2015	% Change	3/2016 Forecast
Pharmaceuticals	67,877	145,712	143,063	70,651	159,261	96,540	36.6	183,283
Prescription pharmaceuticals	64,476	139,257	136,610	67,403	152,556	91,634	35.9	176,792
Ophthalmic	58,638	127,395	124,790	61,732	136,059	84,521	36.9	167,603
Anti-rheumatic drugs	5,256	10,251	10,251	4,835	9,629	3,514	-27.3	3,617
Other prescription pharmaceuticals	581	1,610	1,569	837	6,868	3,599	330.2	5,572
OTC pharmaceuticals	3,400	6,455	6,453	3,248	6,705	4,906	51.0	6,491
Others	1,386	2,950	2,950	1,268	2,569	1,334	5.1	3,217
Medical devices	1,261	2,678	2,678	1,154	2,327	1,179	2.2	2,552
Others	124	272	272	114	242	154	34.9	665
Total net sales	69,263	148,663	146,013	71,920	161,831	97,873	36.1	186,500
[Domestic]							(Milli	ons of yen)

[Domestic]

		J-GAAP				IFRS		
Half year/year to	9/2013	3/2014*	3/2014 [12month]	9/2014	3/2015	9/2015	% Change	3/2016 Forecast
Pharmaceuticals	56,806	119,215	119,184	56,051	122,310	69,102	23.3	129,394
Prescription pharmaceuticals	53,424	112,798	112,767	52,839	115,672	64,238	21.6	122,969
Ophthalmic	47,915	101,779	101,779	47,710	105,345	60,374	26.5	118,483
Anti-rheumatic drugs	5,206	10,162	10,162	4,805	9,568	3,514	-26.9	3,617
Other prescription pharmaceuticals	302	856	825	325	759	350	7.6	869
OTC pharmaceuticals	3,381	6,417	6,417	3,212	6,638	4,864	51.5	6,425
Others	1,364	2,897	2,897	1,257	2,526	1,300	3.4	2,812
Medical devices	1,240	2,625	2,625	1,143	2,283	1,146	0.3	2,500
Others	124	272	272	114	242	154	34.9	312
Total domestic sales	58,171	122,113	122,082	57,308	124,835	70,402	22.8	132,205
(Percentage of total net sales)	84.0%	82.1%	83.6%	79.7%	77.1%	71.9%	-	70.9%

[Overseas]

(Millions of yen) J-GAAP IFRS Half year/year to 3/2016 3/2014 9/2013 3/2014* 9/2014 3/2015 9/2015 % Change Forecast [12month] Pharmaceuticals 11,070 26,497 23,878 14,600 36,952 27,437 87.9 53,890 Prescription pharmaceuticals 11,051 26,459 23,843 14,564 27,396 53,823 36,884 88.1 Ophthalmic 10,723 25,616 23,010 14,022 30,714 24,147 72.2 49,120 Anti-rheumatic drugs 49 88 88 30 61 -100.0 754 743 3,249 Other prescription pharmaceuticals 278 511 6,109 535.3 4,703 OTC pharmaceuticals 19 37 35 42 37 67 13.7 67 Others 21 33 405 52 52 11 43 196.8 21 33 52 52 11 4 196.8 52 Medical devices Others 353 Total overseas sales 11,092 26,550 23,931 14,612 36,995 27,471 88.0 54,295 (Percentage of total net sales) 22.9% 16.0% 17.9% 16.4% 20.3% 28.1% 29.1%

Oversea sales by region

(Millions of yen)

	J-G.	AAP	IFRS						
Half year/year to	9/2013	3/2014*	3/2014	9/2014	3/2015	9/2015	% Change	3/2016	
	2010	0/2011	0/2011	<i>)</i> / = 011	0/2010	<i>)</i> / = 010	,8.	Forecast	
U.S.		1,073	1,016	525	6,169	3,305	529.4	4,937	
Europe		12,294	11,466	6,220	14,156	11,602	86.5	25,414	
Asia	_	13,173	11,700	7,864	16,668	12,562	59.7	23,906	
Others	_	8	7	2	2	2	-5.2	37	
Total oversea sales	-	26,550	24,188	14,612	36,995	27,471	88.0	54,295	
■Oversea profit contribution (IFRS) (Millions of									

Oversea profit contribution (IFRS)

Half year/year to			3/2014	9/2014	3/2015	9/2015	% Change	3/2016 Forecast
U.S.	—	-	-1,124	-431	-1,259	-1,144	165.5	-2,479
Europe	—	—	-74	146	3,592	2,267	1,448.0	3,774
Asia	—	—	1,311	2,084	3,780	4,313	107.0	5,791
Others	—	_	—	_	_	—	—	_
Total oversea sales	_	_	113	1,799	6,113	5,436	202.1	7,086

* After reflecting unification of accounting period.

Sales details

■ Sales of major prescription pharmaceuticals

Therapeutic category	Generic name/formulation	Brand name	Region
			Total
	loveflowerin (on hthe lowing colution	Consta	Japan
	levofloxacin/ophthalmic solution	Cravit	Asia
Bacterial conjunctivitis			Europe
			Total
	ofloxacin/ophthalmic solution	Tarivid	Japan
			Asia
	tafluprost-timolol maleate/		Total
	combination ophthalmic solution	Tapcom	Japan
			Europe
			Total
	tafluprost/opthalmic solution	Tapros	Japan
	1 1	<u>r</u>	Asia
			Europe
			Total
	dorzolamide hydrochloride-timolol maleate/	Cosopt	Japan
	combination ophthalmic solution	1	Asia
			Europe
			Total
Glaucoma	timolol maleate/ophthalmic solution	Timoptol	Japan
	-	-	Asia
			Europe
	timolol maleate/		Total
		Timoptol XE	Japan
	long-acting ophthalmic solution	-	Asia
			Europe
			Total
	dorzolamide hydrochloride/ophthalmic solution	Trusopt	Japan
			Asia Europo
	bunazosin hydrochloride/opthalmic solution	Detantol	Europe
	isopropyl unoprostone/opthalmic solution	Rescula	Japan Japan
	epinastine hydrochloride/ophthalmic solution	Alesion	Japan
Allergy	levocabastine hydrochloride/ophthalmic solution	Livostin	Japan
	levocabastile liyeroemoride/opitilaline solution	Livostin	Total
	sodium hyaluronate/ ophthalmic solution	Hyalein	Japan
	sourum nyaruronate/ opininamite solution	nyaiem	Asia
Corneal disease			Total
	diquafosol sodium	Diquas	Japan
	ulquitosoi soululli	Diquas	Asia
			Total
Inflammation	fluorometholone/ophthalmic solution	Flumetholon	Japan
	spinistic spinistic bolaton		Asia
			Total
Senile cataract	pirenoxine/ophthalmic solution	Kary Uni	Japan
	r · · · · · · · · · · · · · · · · · · ·	1111, C111	Asia
Adjuvant for ophthalmic operations	sodium hyaluronate/ adjuvant for ophthalmic operations	Opegan Hi	Japan
Intravitreal VEGF inhibitor	aflibercept solution for intravitreal injection	Eylea	Japan
	amostept solution for mulavitiear injection	Бунса	Japan

				r/year to	Half yea			
Brand name				IFRS				-GAAP
Di anu nanc	% Change 2016/2015	3/2016 Forecast	% Change 2016/2015	9/2015	3/2015	9/2014	3/2014	9/2013
	7.0	14,331	16.5	8,032	13,399	6,893	13,584	6,760
a .	-0.6	6,461	-6.6	3,280	6,498	3,511	8,175	4,430
Cravit	18.8	6,443	49.9	4,058	5,423	2,707	4,139	1,719
	-3.4	1,428	2.9	694	1,478	674	1,270	610
	-2.3	1,866	13.0	1,086	1,910	961	1,924	974
Tarivid	-11.7	673	-10.4	374	762	418	955	521
	4.0	1,193	31.0	712	1,147	543	969	453
	404.5	1,924	—	637	381	_	_	_
Tapcom	299.3	1,367	_	561	342	_	_	_
1	_	557	—	76	39	_	_	_
	33.1	16,413	32.4	7,729	12,330	5,836	12,516	5,743
-	10.3	9,186	18.2	4,613	8,329	3,902	8,957	4,134
Tapros	41.1	1,152	38.5	550	817	397	520	222
	90.8	6,075	67.0	2,566	3,185	1,536	3,040	1,387
	57.9	19,703	86.6	9,804	12,478	5,255	11,846	5,761
~	2.5	10,955	8.9	5,705	10,689	5,240	11,846	5,761
Cosopt	191.1	2,596	_	1,269	892	15		
	585.7	6,152	_	2,830	897	-	_	_
	81.4	2,299	88.3	1,032	1,267	548	1,185	630
	-0.3	1,213	16.3	637	1,216	547	1,185	630
Timoptol	427.6	1,213	- 10.5	74	29	0	-	
	427.0	932	_	321	22	-	_	_
	1.2	2,009	50.0	1,296	1,984	864	1,931	1,009
	-7.0	1,784	15.6	998	1,918	864	1,931	1,009
Timoptol XE	237.4	1,784 92		45	27	0	1,751	1,007
	237.4	133	_	253	39	-	_	_
	128.7	4,237	469.6	2,193	1,853	385		
	22.4	1,891	194.0	1,132	1,545	385	_	_
Trusopt		625	194.0	296	55	1	_	
	582.2	1,721		290 765	252	1		
Detantol	-2.6	1,721	-2.9	594	1,228	612	1,549	778
Rescula	-2.0	1,197	-2.9	967	1,228	972	2,147	1,097
	-3.3	6,407	75.6	2,745	6,698	1,563	2,147	1,097
Alesion		2,146		2,743	2,263	832	2,103	802
Livostin	-5.2 5.7	2,140	-70.7 5.4	10,407	2,203	9,870	2,333	10,749
Hyalein	-1.9	20,724 15,033	-1.8	7,576	19,011	9,870 7,716	18,179	9,271
11yaiciii	-1.9 32.5	15,033 5,691	-1.8	2,832	4,295	2,154	3,237	
								1,477
Diques	41.6 31.9	11,178 9,785	27.3 24.8	4,576 4,232	7,895 7,419	3,595 3,391	7,938 7,831	3,530 3,530
Diquas				4,232 344	476	3,391 204	107	5,550
	192.6	1,393	68.6					1 907
Flumathalan	4.2	3,970	3.5	2,015	3,811	1,946	3,899	1,807
Flumetholon	-1.7	2,796	-3.3	1,287	2,844	1,330	3,075	1,410
	21.5	1,175	18.2	728	967	616	823	397
Kom Ur!	12.2	4,388	13.8	2,268	3,909	1,993	3,978	1,958
Kary Uni	4.6	3,041	1.5	1,495	2,908	1,473	3,162	1,614
	34.5	1,346	48.8 3.4	773 1,335	1,001 2,574	519 1,291	816 2,868	344 1,433
Opegan Hi	3.3	2,658						

Consolidated balance sheets (J-GAAP)

Assets

At half-year/year end	9/201	.3	3/2014*		9/2014		3/2015	
	Million yen	Propor- tion (%)						
Current assets	139,340	65.8	156,006	67.5	130,321	49.8	154,612	52.2
Cash and deposits	52,786		63,509		47,072		65,944	
Notes and accounts receivable-trade	47,497		52,086		52,304		59,611	
Marketable securities	12,310		13,111		6,503		—	
Merchandise and finished goods	15,751		16,223		14,795		16,035	
Work in process	531		390		321		585	
Raw materials and supplies	3,620		3,417		3,534		4,021	
Deferred tax assets	2,095		2,346		2,244		3,165	
Other current assets	4,749		4,925		3,550		5,252	
Allowance for doubtful receivables	-1		-3		-4		-3	
Fixed assets	72,349	34.2	75,099	32.5	131,311	50.2	141,744	47.8
Tangible assets	28,186	13.3	27,628	12.0	27,731	10.6	29,103	9.8
Buildings and structures	14,346		14,146		13,683		13,265	
Machinery, equipment and vehicles	2,400		2,210		2,255		2,441	
Land	8,251		8,266		8,276		8,072	
Leased assets	142		155		152		146	
Construction in progress	967		816		1,290		3,006	
Other tangibles	2,078		2,032		2,073		2,170	
Intangible assets	15,449	7.3	16,585	7.2	71,205	27.2	73,272	24.7
Goodwill	6,285		6,297		5,741		4,970	
In-process research and development	7,583		8,357		8,193		7,688	
Software	1,193		1,826		1,665		1,918	
Other intangibles	386		102		55,605		58,694	
Investments and other assets	28,713	13.6	30,885	13.4	32,374	12.4	39,368	13.3
Investment securities	20,087		21,739		23,730		33,349	
Deferred tax assets	5,614		5,488		4,941		2,115	
Other assets	3,012		3,657		3,702		3,903	
Total assets	211,690	100.0	231,105	100.0	261,632	100.0	296,357	100.0

*After reflecting unification of accounting period

■Liabilities and net assets

At half-year/year end	9/201	3	3/2014	*	9/201	4	3/201	5
	Million yen	Propor- tion (%)						
Current liabilities	29,218	13.8	39,093	16.9	62,533	23.9	56,162	19.0
Trade accounts payable	10,197		14,270		7,429		14,329	
Short term debt	_		_		35,000		11,767	
Other payables	8,318		9,695		8,733		13,268	
Income taxes payable	5,578		8,169		4,716		6,823	
Reserve for bonuses	2,908		3,573		3,170		3,840	
Provision for sales returns	111		135		142		186	
Other current liabilities	2,104		3,249		3,340		5,945	
Non-current liabilities	10,945	5.2	10,802	4.7	10,897	4.2	35,475	12.0
Lease Obligations	71		59		61		46	
Deferred tax liabilities	2,540		2,796		2,741		2,723	
Retirement and severance benefits	_		_		_		_	
Retirement and severance benefits for directors and auditors	_		_		_		_	
Net defined benefit liability	6,232		5,400		5,657		5,457	
Provision for business structure improvement	739		802		853		766	
Asset retirement obligation	220		221		222		223	
Other liabilities	1,141		1,521		1,360		26,257	
Total liabilities	40,164	19.0	49,896	21.6	73,430	28.1	91,638	30.9
Shareholders' equity	171,177	80.9	175,328	75.9	180,394	68.9	190,015	64.1
Common stock	7,193	3.4	7,264	3.1	7,313	2.8	7,383	2.5
Capital surplus	7,887	3.7	7,958	3.4	8,008	3.1	8,077	2.7
Retained earnings	156,100	73.7	160,115	69.3	165,085	63.1	174,573	58.9
Treasury stock, at cost	-4	-0.0	-9	-0.0	-13	-0.0	-18	-0.0
Accumulated other comprehensive income	-66	-0.0	5,481	2.4	7,237	2.8	14,151	4.8
Unrealized gains on securities, net of taxes	1,846	0.9	4,035	1.7	5,256	2.0	12,048	4.1
Foreign currency translation adjustments	-297	-0.1	2,574	1.1	3,034	1.2	2,845	1.0
Remeasurements of defined benefit plans	-1,614	-0.8	-1,128	-0.5	-1,053	-0.4	-743	-0.3
Stock subscription rights	415	0.2	399	0.2	570	0.2	552	0.2
Total net assets	171,526	81.0	181,209	78.4	188,202	71.9	204,719	69.1
Total liabilities and net assets	211,690	100.0	231,105	100.0	261,632	100.0	296,357	100.0

*After reflecting unification of accounting period.

Consolidated Statement of financial position(IFRS)

Assets

At half-year/year end	3/2014	L I	3/2015	5	9/2015		
		%		%		%	
Non-current assets							
Property, plant and equipment	27,175	11.4	29,104	9.6	28,950	8.2	
Intangible assets	26,610	11.2	84,433	27.8	82,797	23.5	
Financial assets	23,334	9.8	34,725	11.4	35,034	10.0	
Deferred tax assets	5,215	2.2	2,978	1.0	4,089	1.2	
Other non-current assets	2,065	0.9	2,288	0.8	2,039	0.6	
Total non-current assets	84,399	35.5	153,528	50.5	152,909	43.4	
Current assets							
Inventories	19,461	8.2	20,133	6.6	22,011	6.3	
Trade and other receivables	53,986	22.7	61,701	20.3	65,554	18.6	
Other financial assets	4,587	1.9	187	0.1	342	0.1	
Other current assets	2,356	1.0	2,728	0.9	3,252	0.9	
Cash and cash equivalents	72,397	30.5	65,923	21.7	108,011	30.7	
Assets held for sale	454	0.2	_	_	—	_	
Total current assets	153,241	64.5	150,672	49.5	199,171	56.6	
Total assets	237,640	100.0	304,200	100.0	352,080	100.0	

Equity and liabilities

	3/2014	4	3/201	5	9/2015	
		%		%		%
Equity						
Share capital	7,264	3.1	7,383	2.4	7,573	2.2
Capital surplus	7,959	3.4	8,077	2.7	8,268	2.3
Treasury shares	-9	-0.0	-18	-0.0	△ 24	-0.0
Retained earnings	162,727	68.5	178,840	58.8	217,952	61.9
Other components of equity	9,269	3.9	17,497	5.8	17,130	4.9
Total equity attributable to owners of the company	187,210	78.8	211,779	69.6	250,899	71.3
Total equity	187,210	78.8	211,779	69.6	250,899	71.3
Liabilities						
Non-current liabilities						
Financial liabilities	102	0.0	25,351	8.3	19,447	5.5
Net defined benefit liabilities	5,401	2.3	5,459	1.8	5,399	1.5
Provisions	1,467	0.6	1,444	0.5	1,695	0.5
Deferred tax liabilities	2,795	1.2	2,874	0.9	2,621	0.7
Other non-current liabilities	1,479	0.6	953	0.3	1,272	0.4
Total non-current liabilities	11,244	4.7	36,081	11.9	30,435	8.6
Current liabilities						
Trade and other payables	19,072	8.0	20,250	6.7	22,901	6.5
Other financial liabilities	4,880	2.1	19,298	6.3	17,479	5.0
Income tax payable	8,081	3.4	6,729	2.2	22,736	6.5
Provisions	996	0.4	1,197	0.4	1,206	0.3
Other current liabilities	6,157	2.6	8,866	2.9	6,425	1.8
Total current liabilities	39,186	16.5	56,340	18.5	70,746	20.1
Total liabilities	50,430	21.2	92,421	30.4	101,181	28.7
Total equity and liabilities	237,640	100.0	304,200	100.0	352,080	100.0

Consolidated statements of cash flows (J-GAAP)

	-		(Millions of yen)
Half year/year to	9/2013	3/2014*	9/2014
I. Cash flows from operating activities:			
Income before income taxes	13,983	26,893	13,661
Depreciation and amortization	1,336	2,914	2,729
Amortization of goodwill	383	1,012	428
Business structure improvement expenses	867	1,380	—
Increase/decrease in retirement and severance benefits	_	—	—
Increase (decrease) in Net defined benefit liability	409	313	252
Interest and dividend income	-280	-601	-313
Interest expense	3	5	34
Increase/decrease in trade receivables	-3,317	-7,672	-100
Increase/decrease in inventories	1,480	1,650	1,472
Increase/decrease in trade accounts payable	873	4,927	-6,845
Other, net	-1,602	1,589	-230
Subtotal	14,136	32,412	11,088
Interest and dividend income received	289	614	322
Interest expense paid	-1	-2	-31
Income taxes paid	-3,131	-7,066	-8,120
Net cash provided by operating activities	11,293	25,958	3,258
I . Cash flows from investing activities:		120	-
Increase in fixed deposits	-57	-130	-7(
Decrease in fixed deposits	57	111	70
Payments for acquisition of marketable securities	-203	-604	-
Proceeds from sales and redemption of securities	800	2,407	2,103
Payments for acquisition of fixed assets	-2,639	-4,786	-57,808
Proceeds from sale of fixed assets	1	11	68
Purchase of investment securities	-3,911	-4,220	-109
Other, net	-0	515	(
Net cash (used in) provided by investing activities	-5,954	-6,694	-55,745
II . Cash flows from financing activities:			
Proceeds from short-term debt	_	_	35,000
Dividends paid	-4,121	-8,247	-4,127
Other, net	203	294	65
Net cash used in financing activities	-3,918	-7,953	30,937
W . Effect of exchange rate changes on cash and cash equivalents	476	1,289	605
V. Net increase/decrease in cash and cash equivalents	1,897	12,599	-20,943
VI. Cash and cash equivalents at beginning of year	59,797	59,797	72,396
W . Cash and cash equivalents at end of year	61,694	72,396	51,452

*After reflecting unification of accounting period.

Consolidated statements of cash flows (IFRS)

(Millions of year					
Half year/year to	3/2014	9/2014	3/2015	9/2015	
I. Cash flows from operating activities:					
Net profit for the year	19,718	9,759	24,032	43,657	
Depreciation and amortization	2,841	2,738	6,958	4,511	
Impairment losses	216	3	290	313	
Finance income and expenses	-759	-279	-529	-261	
Income tax expenses	10,643	4,781	11,831	21,679	
Decrease (increase) in trade and other receivables	_	_	_	-44,477	
Decrease (increase) in inventories	-8,128	520	-7,701	-3,943	
Decrease (increase) in trade and other payables	1,411	1,471	-521	-1,915	
Decrease (increase) in provisions and retirement benefit liabilities	5,242	-7,001	1,251	2,627	
Gain on disposal of disposal groups	346	211	761	163	
Other	1,883	-811	2,554	-3,264	
Subtotal	33,413	11,391	38,926	19,090	
Interest received	104	44	81	28	
Dividends received	518	279	548	281	
Interest paid	-9	-31	-82	-49	
Income tax paid	-7,340	-8,184	-14,087	-6,965	
Net cash flows from (used in) operating activities	26,686	3,498	25,386	12,385	
I . Cash flows from investing activities: Payments into time deposits	-111	-71	-84	-22	
Proceeds from withdrawal of time deposits	92	71	184	22	
Payments for acquisition of investments	-4,825	-109	-114	-1,963	
Proceeds from sale and redemption of investments	2,933	2,104	4,149	1,310	
Payments for acquisition of property, plant and equipment	-3,461	-990	-2,972	-2,588	
Proceeds from sales of property, plant and equipment	0	0	0	C	
Payments for acquisition of intangible assets	-2,418	-57,035	-63,468	-1,261	
Proceeds on disposal of disposal groups	_	—	-	45,000	
Other	-57	46	596	14	
Net cash flows from (used in) investing activities	-7,847	-55,985	-61,709	40,512	
II. Cash flows from financing activities:					
Proceeds from short-term loans payable	_	35,000	35,000	—	
Repayments of short-term loans payable	_	_	-35,000	_	
Proceeds from long-term loans payable	_	_	40,000	_	
Repayments of long-term loans payable	-29	-14	-2,970	-5,897	
Dividends paid	-8,247	-4,128	-8,264	-4,954	
Other	322	79	194	322	
Net cash flows from (used in) financing activities	-7,954	30,937	28,960	-10,529	
IV. Net increase (decrease) in cash and cash equivalents	10,885	-21,549	-7,363	42,368	
V. Cash and cash equivalents at the beginning of year	60,237	72,397	72,397	65,923	
VI. Effect of exchange rate changes on cash and cash equivalents	1,275	605	889	-280	
VII. Cash and cash equivalents at the end of period	72,397	51,453	65,923	108,011	

Other Consolidated information

■R&D expenditures

	J-GA	AP		IF	RS	
	9/2013	3/2014*	9/2014	3/2015	9/2015	3/2016
	,,_010	0/2011	,,_,,	0/2020	2010	Forecast
Consolidated	8,078	19,040	8,170	17,477	9,243	22,900
Percentage of net sales	11.7%	12.8%	11.4%	10.8%	9.4%	12.3%

Capital expenditures

	J-GA	AAP		IF	RS	
Half year/year to	9/2013	3/2014*	9/2014	3/2015	9/2015	3/2016 Forecast
Consolidated	1,844	3,155	1,354	5,383	1,793	7,650

Depreciation and amortization

	J-GA	AP		IF	RS	
Half year/year to	9/2013	13 3/2014* 9/2014 3/2015		9/2015	3/2016 Forecast	
Manufacturing cost	582	1,330	700	1,446	684	1,440
Selling, general and administrative expenses	289	648	1,704	4,843	3,512	7,080
R&D expenses	302	634	333	669	315	800
Consolidated total	1,174	2,612	2,738	6,958	4,511	9,320

■Number of employees

At half-year/year end	9/2013	3/2014*	9/2014	3/2015	9/2015
Consolidated	3,073	3,072	3,133	3,230	3,330
Sales division	1,353	1,360	1,416	1,510	1,551
Production division	799	785	771	762	779
R&D division	605	604	616	605	606
Corporate or back-office division	316	323	330	353	394

*After reflecting unification of accounting period.

(Millions of yen)

(Millions of yen)

Reference information Research & development

■ Pipeline of prescription pharmaceuticals (Clinical Stage)

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launched	
Tafluprost	DE-085	Glaucoma/	Co-development	Asia						Mar-10	
ranuprost	DE-005	Ocular hypertension	with Asahi Glass	China			Jul-15				
A prostaglandin F _{2a} deriva	tive for the trea	tment of glaucoma and ocular	hypertension. Since De	cember, 2	008, lau	08, launched in Japan, Europe, and the U.S					
In Asia, launched in Hong I	Kong, Korea, Ir	donesia, and Singapore, etc.	Acquired import drug lice	ense in Ch	ina in July 2015.						

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launched
			Marak Charp 9	Korea						Oct-13
Diquafosol sodium	DE-089	Dry eye	Merck Sharp & Dohme Corp. (U.S.)	China				Jan-12		
				Asia					Jul-15	
A dry ove treatment which	stimulatos soci	ation of mucin and aqueous o	omponents from the corr		ium Ite	mochan	icm of c	otion is a		

A dry eye treatment which stimulates secretion of mucin and aqueous components from the corneal epithelium. Its mechanism of action is different from existing treatments. Launched in December 2010 in Japan and in October 2013 in Korea. NDA filed in China in January 2012. Marketing approval in Thailand in July 2015. Marketing approval in Vietnam in October 2015.Currently seeking sequential approvals for marketing in Asia.

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launched
Lomerizine HCI	DE-090	Glaucoma	MSD K.K.	Japan						

A new type of glaucoma treatment which inhibits the progression of visual field defects. It is the only calcium antagonist being development as an oral glaucoma treatment. Compared to NMDA receptor antagonists, it has excellent safety profile with mild systemic adverse drug reactions.

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launched
				U.S.						
Sirolimus	DE-109	Uveitis	Original	Japan						
Circlinido	DE 100	Ovenio	Original	Europe				Feb-15		
				Asia				Apr-15		

An intravitreal injection with immunosuppressive effect, anti-angiogenic effect, etc. Phase 3 study is ongoing in multiple countries including the U.S. NDA filed in Europe in February 2015 and in Asia in April 2015.

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launched
				Japan					1	Nov-14
Tafluprost/	DE-111	Glaucoma/	Co-development	Europe					•	Jan-15
Timolol maleate	DE-III	Ocular hypertension	with Asahi Glass	Korea					Jun-15	
				Asia				Mar-15		

A fixed dose combination drug of a prostaglandin $F_{2\alpha}$ derivative and a beta-adrenergic receptor blocker. Launched in Japan in November 2014. Approved successively in EU countries since October 2014 and Launched since January 2015. Acquired import grug lisence in Korea in June 2015. NDA being filed in Asian countries successively.

[Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launched
	(Undetermined)	DE-117	Glaucoma/ Ocular hypertension	Co-development with Ube Industries	U.S.						

An EP2 receptor agonist with a new mechanism of action. Completed Phase 2b in the U.S in February 2015.

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launched
Tafluprost	DE-118	Glaucoma/	Co-development	Japan						Oct-13
Tanupiosi	DE-110	Ocular hypertension	with Asahi Glass	Asia		Jun-15				
A prostaglandin $F_{2\alpha}$ deriva	tive for the trea	itment of glaucoma and ocula	r hypertension. Preservat	ive-free, si	ngle dos	se type p	product.	Launche	ed in Oct	ober
2013 in Japan. Acquired r	narketing appro	oval in Hong Kong in June 201	5. Seeking sequential ap	provals for	r market	ting in As	sian cou	untries.		

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launched
(Undetermined)	DE-120	Wet Age-related macular degeneration	Original	U.S.						

An intravitreal injection with dual inhibitor of VEGF and PDGF. Started Phase 2a in the U.S. in April 2015.

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launched
(Undetermined)	DE-122	Wet Age-related macular degeneration	Tracon	U.S.	(Phase 1/2					
An intravitreal injection of a	inti-endoglin ar	ntibody. Started Phase1/2 in th	e U.S. in September 20'	15.						

■ Pipeline of prescription pharmaceuticals (Clinical Stage)

Generic name	Dev. name	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launched
Cieleanaria	Cueleket	Severe keratitis in	Original	Europe						Jul-15
Ciclosporin	Cyclokat	patients with dry eye	Original	U.S.						
		evere keratitis in adult patient hed in Germany in July 2015 a					nic emul	lsion tech	nnology I	ias
Generic name	Dev. name	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launched
Ciclosporin	Vekacia	Vernal Keratoconiunctivitis	Original	Europe		1	1			
•		evere keratitis in adult patient hed in Germany and UK in Ju							nnology l	as
Generic name	Dev. name	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Approved	Launched
Generic name Latanoprost	Dev. name Catioprost	Indication Glaucoma/ Ocular hypertension	Original/Licensor Original	Region Europe	P1	P2	P3	NDA Filed	Approved	Launched
Latanoprost	Catioprost	Glaucoma/	Original	Europe		P2	P3	NDA Filed	Approved	Launched
Latanoprost	Catioprost	Glaucoma/ Ocular hypertension	Original	Europe		P2	P3		Approved	

Generic name	Dev. name	Indication	Original/Licensor	Region	P1	P2	P3	NDA Filed	Ap
Dexamethasone Palmitate	Cortiject	Diabetic macular edema	Original	Europe	(Phas	e 1/2)			

An intravitreal injection with anti-inflammatory effect.

Changes from 1Q FY15 (August 4, 2015)

Dev. Code / name	Changes
DE-085	Approved in July 2015 (China)
DE-122	Started Phase1/2 in the U.S. in September 2015

Pharmaceutical market in Japan

■Revision of N	Vational	Health	Insuran	ce (NHI) drug	prices				(%)
	2004	2005	2006	2007 2008	2009 2010	2011	2012	2013	2014
Industry average	-4.2	_	-6.7	— early -5%	— mid -6%	_	-6.3%	_	-2.7%
Ophthalmic drugs	-2.7	_	-5.5	— high -3%	— early -3%	_	mid -4%	_	high -1%
Santen	-3.2	_	-5.3	— mid -3%	— mid -5%	_	high -5%	_	high -1%
								a	

(Compiled by Santen)

Revision of NHI drug prices: In Japan, drug prices are generally revised every two years to reflect their market price. The drugs marketed at lower market prices will bear larger reduction margins at the revision.

Including the consumer tax increase impact

	2014
Industry average	-5.6%
Ophthalmic drugs	high -4%
Santen	high -4%

■Market shares

					(Billions of yen)
Half year/year to	9/2013	3/2014	9/2014	3/2015	9/2015
Prescription ophthalmics	40.3%	39.4%	39.4%	40.1%	43.4%
	141.6	301.3	153.4	323.7	169.1

Notes: - On an NHI drug price basis.

- Lower figures indicate market size.

Copyright IMS Health, 2015 Source: Santen analysis based on IMS JPM Period: 2013.4-2015.9; Unauthorized copy prohibited

Market shares by the	erapeutic area	a - prescription	ophthalmics		(Billions of yen)
Half year/year to	9/2013	3/2014	9/2014	3/2015	9/2015
Glaucoma treatments	30.7%	30.5%	30.9%	32.1%	32.8%
	51.0	104.7	51.4	105.7	56.1
Corneal disease treatments	71.8%	70.5%	66.5%	65.6%	63.9%
	21.4	44.2	21.5	44.2	22.9
Anti-infective	59.9%	58.5%	55.2%	54.0%	50.7%
	9.7	18.3	8.8	16.8	8.7
Anti-allergy	18.3%	21.2%	30.4%	32.0%	36.2%
	10.0	0.3	11.9	33.9	13.0
Anti-VEGF*	51.4%	48.7%	45.7%	48.8%	61.7%
	17.9	0.4	28.5	61.6	37.1


Notes: - On an NHI drug price basis.

- Lower figures indicate market size.

*Anti-Vascular Endothelial Growth Factor

Copyright IMS Health, 2015 Source: Santen analysis based on IMS JPM Period: 2013.4-2015.9; Unauthorized copy prohibited

Stock information



*The Company has conducted a 5-for-1 stock split with an effective date of April 1, 2015. Stock price and Volume before the stock split are calculated based on the stock split rate.

■Major shareholders (top 10)	As of S	September 30, 2015
Name	Number of shares held	Percentage of investment
	Thousand shares	%
Japan Trustee Service Bank, Ltd.(Trust Account)	29,789	7.2
State Street Bank and Trust Company 505223	25,113	6.1
The Master Trust Bank of Japan, Ltd.(Trust Account)	16,855	4.1
Nippon Life Insurance Company	10,662	2.6
The Bank of Tokyo-Mitsubishi UFJ, Ltd.	10,605	2.6
Ono Pharmaceutical Co.,Ltd.	9,307	2.2
Daiichi Sankyo Company,Ltd.	9,180	2.2
Development Bank of Japan Inc.	8,275	2.0
National Mutual Insurance Federation of Agricultural Cooperatives	7,121	1.7
Trust & Custody Services Bank.,Ltd.as trustee for Eisai Co.,Ltd. Retirement Benefit Trust Account re-entrusted by Mizuho Trust and Banking Co.,Ltd	6,863	1.7

Major stock information

	3/2012	3/2013	3/2014	3/2015	9/2015
Issued shares (thousands)	87,146	82,469	82,582	413,266	413,836
Treasury stock (thousands)	1	0	2	19	22
Market Capitalization (million)	308,059	366,983	378,219	723,181	661,688
A purchased amount of money (millions of yen)	_	13,735	_	_	—
The number of the purchased stocks (thousand shares)	_	4,937	_	_	_

*The Company has conducted a 5-for-1 stock split with an effective date of April 1, 2015.

The figures of 3/2015 are calculated based on the assumption that the stock split was conducted at April 1, 2014.


Stock information


At half-year/year end	9/20	13	3/20)14	9/20	14	3/20)15	9/20	15
	Thousand shares	Propor- tion (%)								
Financial institutions	29,315	35.5	28,971	35.1	30,060	36.4	30,049	36.4	146,390	35.4
City & regional banks	2,268	2.7	2,270	2.8	2,257	2.7	2,262	2.7	11,424	2.8
Trust banks	17,875	21.7	17,581	21.3	18,703	22.6	18,726	22.7	98,285	23.8
(concerned in trust works)	15,473	_	15,192	—	16,293	_	16,333	_	86,312	—
Life and non-life insurance	4,414	5.3	4,290	5.2	4,334	5.3	4,196	5.1	21,171	5.1
Other financial institutions	4,757	5.8	4,829	5.8	4,765	5.8	4,862	5.9	15,510	3.7
Securities firms	568	0.7	721	0.9	625	0.8	922	1.1	4,694	1.1
Other institutions	7,900	9.6	7,913	9.6	7,940	9.6	7,880	9.5	37,827	9.1
Foreign investors	37,056	44.9	37,597	45.5	37,208	45.0	36,373	44.0	186,924	45.2
Individual investors	7,694	9.3	7,376	8.9	6,773	8.2	7,423	9.0	37,978	9.2
Treasury Stock	1	0.0	2	0.0	3	0.0	3	0.0	22	0.0
Total	82,537	100.0	82,582	100.0	82,611	100.0	82,653	100.0	413,836	100.0

Breakdown of shareholding by number of shares

Breakdown of shareholding by number of shareholders

At half-year/year end	9/20	13	3/20	14	9/20	14	3/20)15	9/20	15
	Number of	Propor-								
	shareholders	tion (%)								
Financial institutions	59	0.8	56	0.8	58	0.8	62	0.6	70	0.3
City & regional banks	4	0.1	5	0.1	4	0.1	4	0.1	6	0.0
Trust banks	27	0.3	25	0.3	26	0.3	27	0.2	30	0.2
Life and non-life insurance	23	0.3	21	0.3	22	0.3	23	0.2	26	0.1
Other financial institutions	5	0.1	5	0.1	6	0.1	8	0.1	8	0.0
Securities firms	32	0.4	35	0.4	28	0.4	33	0.3	46	0.3
Other institutions	107	1.5	114	1.5	106	1.5	122	1.1	142	0.8
Foreign investors	392	5.3	407	5.2	465	6.7	486	4.2	519	2.9
Individual investors	6,809	92.0	7,167	92.1	6,323	90.6	10,664	93.8	17,380	95.7
Treasury stock	1	0.0	1	0.0	1	0.0	1	0.0	1	0.0
Total	7,400	100.0	7,780	100.0	6,981	100.0	11,368	100.0	18,158	100.0





Consolidated subsidiaries

[Domestic] As of Septe Claire Co., Ltd.	
	mber 50, 2015
Main business Cleaning of antidust and sterilized clothing Location Japan Paid-in capital 90 million yen Equity ow	vned 100%
[Overseas]	
Santen Holdings U.S. Inc. Holding company for North American businesses	
Main business and business development Location U.S.A. Paid-in capital 24,784 thousand US\$ Equity ow	vned 100%
Santen Inc.	
Main business Clinical development and business development Location U.S.A. Paid-in capital 8,765 thousand US\$ Equity ow	vned 100% *1
of pharmaceuticals	
Advanced Vision Science, Inc.	
Main business Research and development, production and marketing of medical devices Location U.S.A. Paid-in capital 10 thousand US\$ Equity ow	vned 100% *1
Santen Holdings EU B.V.	
Main business Holdings company for European operation Location Netherlands Paid-in capital 50 thousand euros Equity ow	vned 100%
Santen Oy	
Main business Development, production and marketing of Location Finland Paid-in capital 20,000 thousand Equity ow	vned 100% *2
pharmaceuticals euros to the euros	100% ·2
Santen S.A.S.	
Main business Development and marketing of pharmaceuticals Location France Paid-in capital 1,976 thousand euros Equity ow	vned 100% *2
Santen GmbH	
Main business Marketing of pharmaceuticals and business development Location Germany Paid-in capital 25 thousand euros Equity ow	vned 100% *2
SantenPharma AB	
Main business Marketing support of pharmaceuticals Location Sweden Paid-in capital 500 thousand S.KR Equity ow	vned 100% *2
Santen Switzerland SA	
Main business Marketing of pharmaceuticals Location Switzerland Paid-in capital 1,657 thousand Swiss 2015	100% *2
Fran Ousliess Warkening of pharmaceureans Escation Switzerhand Franc franc	10070 2
Santen Italy S.r.I.	1 1000/ *2
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow	vned 100% *2
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow Santen UK Limited	
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow Santen UK Limited Main business Marketing of pharmaceuticals Location UK Paid-in capital 2,300 thousand euros Equity ow	
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow Santen UK Limited Main business Marketing of pharmaceuticals Location UK Paid-in capital 2,300 thousand euros Equity ow Santen Pharmaceutical Spain, S.L. Equity ow Equity ow Equity ow Equity ow	vned 100% *2
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow Santen UK Limited Main business Marketing of pharmaceuticals Location UK Paid-in capital 2,300 thousand euros Equity ow Santen Pharmaceutical Spain, S.L. Marketing of pharmaceuticals Location Spain Paid-in capital 3 thousand euros Equity ow	vned 100% *2
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow Santen UK Limited Main business Marketing of pharmaceuticals Location UK Paid-in capital 2,300 thousand euros Equity ow Santen Pharmaceutical Spain, S.L. Main business Marketing of pharmaceuticals Location Spain Paid-in capital 3 thousand euros Equity ow Santen Pharmaceutical (China) Co., Ltd. Development production and marketing of Development production and marketing of Development production Marketing of	vned 100% *2 vned 100% *2
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow Santen UK Limited Main business Marketing of pharmaceuticals Location UK Paid-in capital 2,300 thousand euros Equity ow Santen Pharmaceutical Spain, S.L. Main business Marketing of pharmaceuticals Location Spain Paid-in capital 3 thousand euros Equity ow Santen Pharmaceutical Spain, S.L. Spain Paid-in capital 3 thousand euros Equity ow Santen Pharmaceutical (China) Co., Ltd. Location Spain Paid-in capital 3 thousand euros Equity ow	vned 100% *2 vned 100% *2
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow Santen UK Limited Main business Marketing of pharmaceuticals Location UK Paid-in capital 2,300 thousand euros Equity ow Santen Pharmaceutical Spain, S.L. Main business Marketing of pharmaceuticals Location Spain Paid-in capital 3 thousand euros Equity ow Santen Pharmaceutical (China) Co., Ltd. Santen Pharmaceutical (China) Co., Ltd. Equity ow Equity ow Santen Pharmaceuticals Location China Paid-in capital 3,800 million yen Equity ow Santen Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd. Equity ow Equity ow	vned 100% *2 vned 100% *2
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow Santen UK Limited Main business Marketing of pharmaceuticals Location UK Paid-in capital 2,300 thousand euros Equity ow Santen Pharmaceutical Spain, S.L. Main business Marketing of pharmaceuticals Location Spain Paid-in capital 3 thousand euros Equity ow Santen Pharmaceutical (China) Co., Ltd. Main business Development, production and marketing of pharmaceuticals Location China Paid-in capital 3,800 million yen Equity ow Santen Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd. Marketing of pharmaceuticals Location China Paid-in capital 3,800 million yen Equity ow	vned 100% *2 vned 100% *2 vned 100%
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow Santen UK Limited Main business Marketing of pharmaceuticals Location UK Paid-in capital 2,300 thousand euros Equity ow Santen Pharmaceutical Spain, S.L. Main business Marketing of pharmaceuticals Location Spain Paid-in capital 3 thousand euros Equity ow Santen Pharmaceutical (China) Co., Ltd. Santen Pharmaceutical (China) Co., Ltd. Spain Paid-in capital 3,800 million yen Equity ow Santen Pharmaceuticals Location China Paid-in capital 3,800 million yen Equity ow Santen Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd. Main business Marketing of pharmaceuticals Location China Paid-in capital 10,000 thousand RMB Equity ow	vned 100% *2 vned 100% *2 vned 100%
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow Santen UK Limited Main business Marketing of pharmaceuticals Location UK Paid-in capital 2,300 thousand euros Equity ow Santen Pharmaceutical Spain, S.L. Main business Marketing of pharmaceuticals Location Spain Paid-in capital 3 thousand euros Equity ow Santen Pharmaceutical China) Co., Ltd. Santen Pharmaceutical (China) Co., Ltd. Development, production and marketing of pharmaceuticals Location China Paid-in capital 3,800 million yen Equity ow Santen Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd. Main business Marketing of pharmaceuticals Location China Paid-in capital 10,000 thousand RMB Equity ow Santen Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd. Main business Marketing of pharmaceuticals Location China Paid-in capital 10,000 thousand RMB Equity ow Santen Pharmaceutical Korea Co., Ltd. Equity ow Equity ow Equity ow Equity ow	vned 100% *2 vned 100% *2 vned 100% vned 100% *3
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow Santen UK Limited Main business Marketing of pharmaceuticals Location UK Paid-in capital 2,300 thousand euros Equity ow Santen Pharmaceutical Spain, S.L. Main business Marketing of pharmaceuticals Location Spain Paid-in capital 3 thousand euros Equity ow Santen Pharmaceutical China) Co., Ltd. Santen Pharmaceuticals Location Spain Paid-in capital 3,800 million yen Equity ow Santen Pharmaceuticals Location China Paid-in capital 3,800 million yen Equity ow Santen Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd. Main business Marketing of pharmaceuticals Location China Paid-in capital 10,000 thousand RMB Equity ow	vned 100% *2 vned 100% *2 vned 100% vned 100% *3
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow Santen UK Limited Main business Marketing of pharmaceuticals Location UK Paid-in capital 2,300 thousand euros Equity ow Santen Pharmaceutical Spain, S.L. Main business Marketing of pharmaceuticals Location Spain Paid-in capital 3 thousand euros Equity ow Santen Pharmaceutical (China) Co., Ltd. Main business Development, production and marketing of pharmaceuticals Location China Paid-in capital 3,800 million yen Equity ow Santen Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd. Main business Marketing of pharmaceuticals Location China Paid-in capital 10,000 thousand RMB Equity ow Santen Pharmaceutical Korea Co., Ltd. Marketing of pharmaceuticals Location China Paid-in capital 10,000 thousand RMB Equity ow Santen Pharmaceutical Korea Co., Ltd. Marketing of pharmaceuticals Location China Paid-in capital 29,000,000 thousand RMB Equity ow	vned 100% *2 vned 100% *2 vned 100% vned 100% *3
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow Santen UK Limited Main business Marketing of pharmaceuticals Location UK Paid-in capital 2,300 thousand euros Equity ow Santen Pharmaceutical Spain, S.L. Main business Marketing of pharmaceuticals Location Spain Paid-in capital 3 thousand euros Equity ow Santen Pharmaceutical (China) Co., Ltd.	vned 100% *2 vned 100% *2 vned 100% vned 100% *3 vned 100%
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow Santen UK Limited Main business Marketing of pharmaceuticals Location UK Paid-in capital 2,300 thousand euros Equity ow Santen Pharmaceutical Spain, S.L. Main business Marketing of pharmaceuticals Location Spain Paid-in capital 3 thousand euros Equity ow Santen Pharmaceutical (China) Co., Ltd. Main business Development, production and marketing of pharmaceuticals Location China Paid-in capital 3,800 million yen Equity ow Santen Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd. Equity ow Santen Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd. In 0,000 thousand RMB Equity ow Santen Pharmaceutical Korea Co., Ltd. Development, import and marketing of pharmaceuticals Location China Paid-in capital 10,000 thousand RMB Equity ow Santen Pharmaceutical Korea Co., Ltd. Main business Marketing of pharmaceuticals Location China Paid-in capital 10,000 thousand RMB Equity ow Santen Pharmaceutical Korea Co., Ltd. Main business Development, import and marketi	vned 100% *2 vned 100% *2 vned 100% vned 100% *3 vned 100%
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow Santen UK Limited Main business Marketing of pharmaceuticals Location UK Paid-in capital 2,300 thousand euros Equity ow Santen Pharmaceutical Spain, S.L. Main business Marketing of pharmaceuticals Location Spain Paid-in capital 3 thousand euros Equity ow Santen Pharmaceutical (China) Co., Ltd. Development, production and marketing of pharmaceuticals Location China Paid-in capital 3,800 million yen Equity ow Santen Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd. Main business Marketing of pharmaceuticals Location China Paid-in capital 10,000 thousand RMB Equity ow Santen Pharmaceutical Korea Co., Ltd. Main business Marketing of pharmaceuticals Location China Paid-in capital 10,000 thousand RMB Equity ow Santen Pharmaceutical Korea Co., Ltd. Main business Development, import and marketing of harmaceuticals Location Korea Paid-in capital 29,000,000 thousand won Equity ow Taiwan Santen Pharmaceutical Co., Ltd. Main busin	vned 100% *2 vned 100% *2 vned 100% vned 100% *3 vned 100% vned 100%
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow Santen UK Limited Main business Marketing of pharmaceuticals Location UK Paid-in capital 2,300 thousand euros Equity ow Santen Pharmaceutical Spain, S.L. Main business Marketing of pharmaceuticals Location Spain Paid-in capital 3 thousand euros Equity ow Santen Pharmaceutical (China) Co., Ltd. Main business Development, production and marketing of pharmaceuticals Location China Paid-in capital 3,800 million yen Equity ow Santen Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd. Equity ow Santen Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd. In 0,000 thousand RMB Equity ow Santen Pharmaceutical Korea Co., Ltd. Development, import and marketing of pharmaceuticals Location China Paid-in capital 10,000 thousand RMB Equity ow Santen Pharmaceutical Korea Co., Ltd. Main business Marketing of pharmaceuticals Location China Paid-in capital 10,000 thousand RMB Equity ow Santen Pharmaceutical Korea Co., Ltd. Main business Development, import and marketi	vned 100% *2 vned 100% *2 vned 100% vned 100% *3 vned 100% vned 100%
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow Santen UK Limited Main business Marketing of pharmaceuticals Location UK Paid-in capital 2,300 thousand euros Equity ow Santen Pharmaceutical Spain, S.L. Main business Marketing of pharmaceuticals Location Spain Paid-in capital 3 thousand euros Equity ow Santen Pharmaceutical (China) Co., Ltd. Main business Development, production and marketing of pharmaceuticals Location China Paid-in capital 3,800 million yen Equity ow Santen Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd. Main business Marketing of pharmaceuticals Location China Paid-in capital 10,000 thousand RMB Equity ow Santen Pharmaceutical Korea Co., Ltd. Main business Marketing of pharmaceuticals Location China Paid-in capital 29,000,000 thousand RMB Equity ow Santen Pharmaceutical Korea Co., Ltd. Main business Development, import and marketing of pharmaceuticals Location Korea Paid-in capital 29,000,000 thousand woon Equity ow Taiwan Santen Pharmaceuticals	Image: Market
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow Santen UK Limited Main business Marketing of pharmaceuticals Location UK Paid-in capital 2,300 thousand euros Equity ow Santen Pharmaceutical Spain, S.L. Main business Marketing of pharmaceuticals Location Spain Paid-in capital 3 thousand euros Equity ow Santen Pharmaceutical (China) Co., Ltd. Development, production and marketing of pharmaceuticals Location China Paid-in capital 3,800 million yen Equity ow Santen Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd. Main business Marketing of pharmaceuticals Location China Paid-in capital 10,000 thousand RMB Equity ow Santen Pharmaceutical Korea Co., Ltd. Main business Development, import and marketing of pharmaceuticals Location Korea Paid-in capital 29,000,000 thousand won Equity ow Taiwan Santen Pharmaceutical Co., Ltd. Main business Import and marketing of pharmaceuticals Location Korea Paid-in capital 42,000 thousand Taiwan dollars Equity ow Santen India Private Limited Main business </td <td>vned 100% *2 vned 100% *2 vned 100% *3 vned 100% *3</td>	vned 100% *2 vned 100% *2 vned 100% *3
Main businessMarketing of pharmaceuticalsLocationItalyPaid-in capital10 thousand eurosEquity owSanten UK LimitedMain businessMarketing of pharmaceuticalsLocationUKPaid-in capital2,300 thousand eurosEquity owSanten Pharmaceutical Spain, S.L.Main businessMarketing of pharmaceuticalsLocationSpainPaid-in capital3 thousand eurosEquity owSanten Pharmaceutical (China) Co., Ltd.Main businessDevelopment, production and marketing of pharmaceuticalsLocationChinaPaid-in capital3,800 million yenEquity owSanten Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd.Main businessMarketing of pharmaceuticalsLocationChinaPaid-in capital10,000 thousand RMBEquity owSanten Pharmaceutical Korea Co., Ltd.Main businessDevelopment, import and marketing of pharmaceuticalsLocationChinaPaid-in capital29,000,000 thousand montEquity owSanten Pharmaceutical Co., Ltd.Main businessDevelopment, import and marketing of pharmaceuticalsLocationKoreaPaid-in capital29,000,000 thousand Taiwan dollarsEquity owTaiwan Santen Pharmaceutical Co., Ltd.Main businessImport and marketing of pharmaceuticalsLocationTaiwanPaid-in capital42,000 thousand Taiwan dollarsEquity owSanten India Private LimitedLocationTaiwanPaid-in capital48,500 thousand India rupeeEquity owSanten Pharmaceut	vned 100% *2 vned 100% *2 vned 100% *3
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow Santen UK Limited Marketing of pharmaceuticals Location UK Paid-in capital 2,300 thousand euros Equity ow Santen Pharmaceutical Spain, S.L. Marketing of pharmaceuticals Location Spain Paid-in capital 3 thousand euros Equity ow Santen Pharmaceutical (China) Co., Ltd. Main business Development, production and marketing of pharmaceuticals Location China Paid-in capital 3,800 million yen Equity ow Santen Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd. Marketing of pharmaceuticals Location China Paid-in capital 10,000 thousand RMB Equity ow Santen Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd. Main business Marketing of pharmaceuticals Location China Paid-in capital 29,000,000 thousand Won Equity ow Santen Pharmaceutical Korea Co., Ltd. Main business Development, import and marketing of pharmaceuticals Location Korea Paid-in capital 29,000,000 thousand Taiwan dollars Equity ow Santen Pharmaceutical Co., Ltd. Main business Import	vned 100% *2 vned 100% *2 vned 100% *3
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow Santen UK Limited Main business Marketing of pharmaceuticals Location UK Paid-in capital 2,300 thousand euros Equity ow Santen Pharmaceutical Spain, S.L. Main business Marketing of pharmaceuticals Location Spain Paid-in capital 3 thousand euros Equity ow Santen Pharmaceutical (China) Co., Ltd. Main business Development, production and marketing of pharmaceuticals Location China Paid-in capital 3,800 million yen Equity ow Santen Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd. Main business Marketing of pharmaceuticals Location China Paid-in capital 10,000 thousand RMB Equity ow Santen Pharmaceutical Korea Co., Ltd. Main business Development, import and marketing of pharmaceuticals Location Korea Paid-in capital 29,000,000 thousand won Equity ow Taiwan Santen Pharmaceutical Co., Ltd. Main business Import and marketing of pharmaceuticals Location Taiwan Paid-in capital 42,000 thousand won Equity ow Santen India Private Limited	vned 100% *2 vned 100% *2 vned 100% vned 100% *3 vned 100% *3 vned 100% vned 100% vned 100% *3 vned 100% vned 100% vned 100% vned 100%
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ow Santen UK Limited Marketing of pharmaceuticals Location UK Paid-in capital 2,300 thousand euros Equity ow Santen Pharmaceutical Spain, S.L. Main business Marketing of pharmaceuticals Location Spain Paid-in capital 3 thousand euros Equity ow Santen Pharmaceutical (China) Co., Ltd. Main business Development, production and marketing of pharmaceuticals Location China Paid-in capital 3,800 million yen Equity ow Santen Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd. Main business Marketing of pharmaceuticals Location China Paid-in capital 10,000 thousand RMB Equity ow Santen Pharmaceutical Korea Co., Ltd. Main business Marketing of pharmaceuticals Location China Paid-in capital 29,000,000 thousand RMB Equity ow Santen Pharmaceutical Korea Co., Ltd. Main business Development, import and marketing of Location Korea Paid-in capital 29,000,000 thousand RMB Equity ow Taiwan Santen Pharmaceutical Co., Ltd. Main business Import and marketing of ph	vned 100% *2 vned 100% *2 vned 100% vned 100% *3 vned 100% *3 vned 100% vned 100% vned 100% *3 vned 100% vned 100% vned 100% vned 100%
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ox Santen UK Limited	vned 100% *2 vned 100% *2 vned 100% vned 100% *3 vned 100% *3 vned 100%
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ox Santen UK Limited Main business Marketing of pharmaceuticals Location UK Paid-in capital 2,300 thousand euros Equity ox Santen Pharmaceutical Spain, S.L. Main business Marketing of pharmaceuticals Location Spain Paid-in capital 3 thousand euros Equity ox Santen Pharmaceutical (China) Co., Ltd. Development, production and marketing of pharmaceuticals Location China Paid-in capital 3,800 million yen Equity ox Santen Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd. Main business Marketing of pharmaceuticals Location China Paid-in capital 10,000 thousand RMB Equity ox Santen Pharmaceutical Korea Co., Ltd. Main business Development, import and marketing of pharmaceuticals Location Korea Paid-in capital 29,000,000 thousand RMB Equity ow Taiwan Santen Pharmaceutical Co., Ltd. Main business Import and marketing of pharmaceuticals Location Taiwan Paid-in capital 42,000 thousand Taiwan dollars Equi	vned 100% *2 vned 100% *2 vned 100% vned 100% *3 vned 100% *3 vned 100%
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ox Santen UK Limited	vned 100% *2 vned 100% *2 vned 100% vned 100% *3 vned 100% *3 vned 100%
Main business Marketing of pharmaceuticals Location Italy Paid-in capital 10 thousand euros Equity ox Santen UK Limited Location UK Paid-in capital 2,300 thousand euros Equity ox Santen Pharmaceutical Spain, S.L. Main business Marketing of pharmaceuticals Location Spain Paid-in capital 3 thousand euros Equity ow Santen Pharmaceutical (China) Co., Ltd. Paid-in capital 3,800 million yen Equity ow Santen Pharmaceutical Sales and Marketing (Suzhou) Co., Ltd. Paid-in capital 10,000 thousand RMB Equity ow Santen Pharmaceutical Korea Co., Ltd. Paid-in capital 10,000 thousand RMB Equity ow Santen Pharmaceuticals Location China Paid-in capital 10,000 thousand RMB Equity ow Santen Pharmaceuticals Location Korea Paid-in capital 29,000,000 thousand RMB Equity ow Santen Pharmaceuticals Location Taiwan Paid-in capital 42,000 thousand India rupee <	vned 100% *2 vned 100% *2 vned 100% *3 vned 100% *3 vned 100% *3 vned 100% vned 100% *3 vned 100% vned 100% vned 100% vned 100% vned 100% vned 100% *4

*1: Indirect investment through Santen Holdings U.S. Inc.
*2: Indirect investment through Santen Holdings EU B.V.
*3: Indirect investment through Santen Pharmaceutical (China) Co., Ltd.

*4 : Indirect investment through Santen Pharmaceutical Asia Pte. Ltd.

News releases

News releases during April 2015-September 2015

For details, please refer to our Website (http://www.santen.com).

2015

- 10-Apr Notice of Change in Significant Shareholder
- 27-Apr Santen Launches New Sante de U a, an OTC Eye Drop
- 1-May Santen Makes Contributions to Support the Recovery of Areas Affected by the Earthquake in Nepal
- 12-May Santen Announces Assignment of its Anti-Rheumatic Pharmaceuticals Business to Hyperion Pharma Santen Pharmaceutical announced today that it has resolved at its board of directors meeting held on May 12, 2015 to enter an agreement with Showa Yakuhin Kakou Co., Ltd. ("Showa Yakuhin") and Hyperion Pharma* Co., Ltd. ("Hyperion") to assign its anti-rheumatic pharmaceuticals business to Hyperion, under a simplified company-split method under the Company Act of Japan ("Assignment"). On the same date, Santen, Hyperion, and Showa have entered into the agreement on the Assignment. Showa Yakuhin is a pharmaceutical company, which is under an investment fund, being advised by Unison Capital, Inc. ("Unison"). *Currently AYUMI Pharmaceutical Corporation

24-Jun Santen Launches COSOPT Mini Combination ophthalmic solution for the Treatment of Glaucoma and Ocular Hypertension

Santen Pharmaceutical announced today that it has launched COSOPT Mini Combination ophthalmic solution (generic name: dorzolamide hydrochloride/timolol maleate; hereinafter "COSOPT Mini") for the treatment of glaucoma and ocular hypertension in the Japanese market. COSOPT Mini is a preservative-free solution in single-dose sterile disposable vial with the same active ingredients as COSOPT Combination ophthalmic solution which contains TRUSOPT ophthalmic solution 1% (generic name: dorzolamide hydrochloride), a carbonic anhydrase inhibitor, and TIMOPTOL ophthalmic solution 0.5% (generic name: timolol maleate), a beta-adrenergic receptor blocker agent.

26-Jun Intravitreal VEGF Inhibitor "EYLEA" Approved as a Treatment of Retinal Vein Occlusion(RVO)

Bayer Yakuhin, Ltd. (Osaka, hereinafter Bayer Yakuhin) and Santen Pharmaceutical Co., Ltd. (Osaka) announced today that Bayer Yakuhin has received approval for the treatment of macular edema secondary to retinal vein occlusion (RVO) for the intravitreal VEGF* inhibitor EYLEA® solution for intravitreal injection 40 mg/mL and EYLEA® intravitreal injection KIT 40 mg/mL (aflibercept [genetical recombination]).

1-Jul Santen Pharmaceutical Announces IND Filing of DE-122 (TRC105) for the Treatment of Wet Age-Related Macular Degeneration

Santen Pharmaceutical announced that it filed an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) for the initiation of clinical studies for DE-122 in patients with wet AMD. DE-122 is the ophthalmic formulation of TRACON Pharmaceuticals' (California, USA) proprietary anti-endoglin antibody, TRC105.

15-Jul Santen Launches Ikervis in Germany

Santen announced the launch of Ikervis (generic name: ciclosporin) for treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes, in Germany. Ikervis will be launched sequentially in Europe. Ikervis is the first drug for the treatment of severe keratitis in adult patients with dry eye disease in Europe.

3-Aug Notice of Completion of the Transfer of Anti-Rheumatic Pharmaceutical Business to AYUMI Pharmaceutical Corporation

4-Aug Santen to Grant Subscription Rights to New Shares as Stock Options for Stock-Linked Remuneration

25-Aug Santen Announces Approval of TAPROS for the Treatment of Open-Angle Glaucoma and Ocular Hypertension in China

Santen Pharmaceutical announced today that it received an import drug license of TAPROS Ophthalmic Solution 0.0015% (generic name: tafluprost) for the treatment of open-angle glaucoma and ocular hypertension in China on July 27, 2015 with required procedures completed on August 21st.

1-Sep Notice on Details of Subscription Rights to New Shares (Stock Options for Stock-Linked Remuneration)



SANTEN PHARMACEUTICAL CO., LTD.